Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Liver Cancer. According to GlobalData, Phase I drugs for Liver Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Linavonkibart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Linavonkibart overview
Linavonkibart (SRK-181) is under development for the treatment of solid tumors including but not limited to head and neck squamous cell carcinoma (HNSCC), urothelial cancer, non-small cell lung cancer, melanoma, clear cell renal cell carcinoma (ccRCC), myelofibrosis , breast cancer and ovarian cancer, oropharyngeal cancer, nasopharyngeal cancer, liver cancer, uterine cancer, prostate cancer and colorectal cancer. It acts by targeting transforming growth factor beta 1 (TGFB1). The drug candidate is developed using the supracellular activation technology platform.
Linavonkibart (SRK-181) was under development for the treatment of bladder cancer, myelofibrosis, breast cancer.
Scholar Rock overview
Scholar Rock, a subsidiary of Scholar Rock Holding Corp, is a biopharmaceutical company that discover and develops therapies for serious diseases. The company’s pipeline products include Apitegromab, a selective anti-latent myostatin for the indication of spinal muscular atrophy and cardiometabolic disorders. Solar Rock other pipeline include SRK-439 (antimyostatin antibody) and SRK-181 a selective, context-independent inhibitor of latent TGF-ß1 activation, designed to target latent TGF-ß1 across all tumors in field of immuno-oncology. The company also develops therapeutics for the treatment of fibrosis and anemia. Scholar Rock is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Linavonkibart’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
